Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-04-26
2011-04-26
Desai, Rita J (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S301000
Reexamination Certificate
active
07932390
ABSTRACT:
There are provided compounds of the formulawherein R1, R2, R3, X, ring A and ring B are as described. The compounds exhibit anticancer properties.
REFERENCES:
patent: 5985853 (1999-11-01), Laugraud et al.
patent: 2001/0020030 (2001-09-01), Stewart et al.
patent: 2004/0097485 (2004-05-01), Burkitt et al.
patent: 2005/0020619 (2005-01-01), Betschmann et al.
patent: 2005/0026944 (2005-02-01), Betschmann et al.
patent: 2005/0043347 (2005-02-01), Betschmann et al.
patent: 2005/0256154 (2005-11-01), Luke et al.
patent: WO 96/32399 (1996-10-01), None
patent: WO 99/62890 (1999-12-01), None
patent: WO 00/71532 (2000-11-01), None
patent: WO 02/44158 (2002-06-01), None
patent: WO 03/082272 (2003-10-01), None
patent: WO 2004/100947 (2004-11-01), None
patent: WO 2005/056562 (2005-06-01), None
Blackburn et. al. “Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors” Bioorganic & Medicinal Chemistry Letters 20 (2010) 4795-4799.
Mulvihill et. al. “1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors” Bioorganic & Medicinal Chemistry Letters 2007, 17, 1091-1097.
Mulvihill et. al. “Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors” Bioorganic & Medicinal Chemistry 2008, 16, 1359-1375.
Miyazaki et. al. “Design and effective synthesis of novel templates, 3,7-diphenyl-4- amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases” Bioorganic & Medicinal Chemistry Letters 2007, 17, 250-254.
Liu et. al. “Synthesis and SAR of 1,9-dihydro-9-hydroxypyrazolo[3,4-b]quinolin-4-ones as novel, selective c-Jun N-terminal kinase inhibitors” Bioorganic & Medicinal Chemistry Letters 2006, 16, 2590-2594.
Jiang et. al. “3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors.” Bioorganic & Medicinal Chemistry Letters 2007, 17, 6378-6382.
Michelotti et. al. “Two classes of p38a MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes” Bioorganic & Medicinal Chemistry Letters 2005, 15, 5274-5279.
Avruch et al., TIBS (19), pp. 279-283 (1994).
Magnuson et al., Cancer Biology, 5, pp. 247-253 (1994).
Sridhar et al., Mol Cancer Ther 2005, 4(4), pp. 677-685 Apr. 2005.
Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 456-457.
Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 196, 197.
Bollag et al., Current Opinion in Investigational Drugs, 4, vol. 12, pp. 1436-1441 (2003).
Strumberg et al., Onkologie, vol. 28 pp. 101-107 (2005).
Beeram et al., J. Clin. Oncol. vol. 23 pp. 6771-6790 (2005).
Sharma et al., Cancer Research vol. 65 pp. 2412-2421 (2005).
AACR American Association for Cancer Research 93rdAnnual Meeting, Apr. 6-10, 2002, San Francisco, California vol. 43, p. 1082.
ASCO 2002 Annual Meeting, Clinical Pharmacology, Preclinical Development of CP-547-632, A Novel VEGFR-2 inhibitor for cancer therapy.
Beebe et al., Cancer Research vol. 63, Nov. 1, 2003, pp. 7301-7309.
Chen Yi
Luk Kin-Chun
Rossman Pamela Loreen
So Sung-Sau
Desai Rita J
Hoffman-La Roche Inc.
Johnston George W.
O'Dell David K
Rocha-Tramaloni Patrica S.
LandOfFree
Substituted thieno[3,2-C]pyridine carboxylic acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted thieno[3,2-C]pyridine carboxylic acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted thieno[3,2-C]pyridine carboxylic acid derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2683003